David Miklos, MD, PhD, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
David Miklos, MD, PhD, clinical director of the CAR T-Cell Therapy Program and Associate Professor of Medicine at the Stanford University Medical Center, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
The ZUMA-2 trial was for patients with mantle cell lymphoma (MCL) who had failed 2 prior lines of therapy and were refractory to BTK inhibitors, and Miklos says that once a patient fails the BTK inhibitor, the patients are usually not able to achieve long-term remissions.
He highlights the overall response rate and complete remission in the trial, and the durable response rate for patients who had follow-up of 2 years. MCL has an important leukemic stage in which physicians could use blood-based next-generation sequencing technologies such as the ClonoSEQ assay to detect the number of cancer cells in a patient, Miklos says, and a portion of the patients in ZUMA-2 who were tested that way showed undetectable minimal residual disease.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More